It’s new-drug-journal-club time! In a world bereft of (many) therapeutic options for sickle cell disease, we want to introduce you to the newest kid on the block: voxelotor. But first, we have to determine if this is a relationship worth starting, and we’ll do that by looking at the data.
Read More